The relationship among hypoxia, proliferation, and outcome in patients with de nouo glioblastoma: A pilot study

Translational Oncology

Volumn 3, Issue 3, 2010, Pages 160-169

  Evans, Sydney M ^a   Jenkins, Kevin W ^a   Chen, H Isaac ^a   Jenkins, W Timothy ^a   Judy, Kevin D ^a   Hwang, Wei Ting ^a   Lustig, Robert A ^a   Judkins, Alexander R ^b   Grady, M Sean ^a   Hahn, Stephen M ^a   Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; HOE 33342; KI 67 ANTIGEN;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; FOLLOW UP; FROZEN SECTION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PREDICTION AND FORECASTING; PROGNOSIS; TUMOR GROWTH;

EID: 77954681705     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09265     Document Type: Article

References (54)

1. Stupp R, Dietrich PY, OstermannKraljevic S, Pica A, Maillard I, Maederl P, Meuli R, Janzer R, Pizzolato G, Miralbell R, et al. (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20,1375-1382.
2. Wen PY and Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507.
3. Brahimi-Horn MC, Chiche J, and Pouyssegur J (2007). Hypoxia and cancer. J Mol Med 85, 1301-1307.
4. Evans SM and Koch CJ (2003). Prognostic significance of tumor oxygenation in humans. Cancer Lett 195, 1-16.
5. Shannon AM, Bouchier-Hayes DJ, Condron CM, and Toomey D (2003). Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29, 297-307.
6. Loges S, Mazzone M, Hohennsinner P, and Carmelliet P (2009). Silencing or fueling metastasis with VEGF inhibitors: angiogenesis revisited. Cancer Cell 15, 167-170.
7. Fernandez Y, Espana L, Manas S, Fabra A, and Sierra A (2000). Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ 7, 350-359.
8. Deryugina E and Quigley J (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25, 9-34.
9. Evans S, Judy K, Dunphy I, Jenkins W Nelson P, Collins R, Wileyt E, Jenkins K, Hahn S, Stevens C, et al. (2004). Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64, 1886-1892.
10. Brown DC and Gatter KC (2002). Ki67 protein: the immaculate deception? Histopathology 40, 2-11.
11. Torp SH (2002). Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin NeuropathoI 21, 252-257.
12. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, and Figarella-Branger D (1998). Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neu-robiol 24, 381-388.
13. Koch CJ (2002). Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 352, 3-31.
14. Koch CJ, Evans SM, and Lord EM (1995). Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72, 869-874.
15. Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, and Koch CJ (2007). Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 69, 1024-1031.
16. Hoskin PJ, Sibtain A, Daley FM, Saunders MI, and Wilson GD (2004). The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 72, 159-168.
17. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, and Kaanders JH (2008). Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncol 44, 335-344.
18. van Laarhoven HW, Kaanders JH, Lok J, Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, and van der Kogel AJ (2006). Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 64, 473-482.
19. Ranelli N, Evans SM, and Judy KD (2009). Role of hypoxia in human brain tumors. Neurosurg Q 19(1), 1-12.
20. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, and Krisch RE (1993). Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials [see comments]. J Natl Cancer Inst 85, 704-710.
21. Urtasun RC, Chapman JD, Feldstein ML, Band RP, Rabin HR, Wilson AF, Marynowski B, Starreveld E, and Shnitka T (1978). Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl 3, 271-275.
22. Koch CJ, Hahn SM, Rockwell K Jr, Covey JM, McKenna WG, and Evans SM (2001). Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-l-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol48, 177-187.
23. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, et al. (2000). Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60, 2018-2024.
24. Evans S, Hahn S, Magarelli D, and Koch C (2001). Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis and proliferation. Am J Clin Oncol 24, 467-472.
25. Koch CJ (2008). Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Radiat Res 169(6), 677-688.
26. Evans S, Judy K, Dunphy I, Jenkins W, Nelson P, Collins R, Wileyto E, Jenkins K, Hahn S, Stevens CW, et al. (2004). Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64, 1886-1892.
27. Evans SM (2006). Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Dermatol 126, 2596-2606.
28. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, and Curran WJ Jr (1998). Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40, 51-55.
29. Kaplan E and Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 4, 57-81.
30. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50, 163-170.
31. Cox D (1972). Regression models and life tables. JR Stat Soc Series B StatMeth-odol 34, 187-220.
32. Evans SM, Fraker DL, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang W-T, Zhang P, and Koch CJ (2006). EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 64(3), 922-927.
33. Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, and Knisely JP (2006). The interactions of polarographic measurements of oxygen tension and histological grade in human glioma [see comment]. Cancer J 12, 461-466.
34. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, and Workman P (1994). Direct measurement of Po2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29, 427-431.
35. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, and Dewhirst MW (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38, 285-289.
36. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, and Broder GJ (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14, 831-838.
37. Vanselow B, Eble MJ, Rudat V, Wollensack P, Conradt C, and Dietz A (2000). Oxygenation of advanced head and neck cancer: prognostic marker for the response to primary radiochemotherapy. Otolaryngol Head Neck Surg 122, 856-862.
38. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, and von Smitten K (1993). Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68, 579-583.
39. Grabenbauer GG, Muhlfriedel C, Rodel F, Niedobitek G, Hornung J, Rodel C, Martus P, Iro H, Kirchner T, Steininger H, et al. (2000). Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 48, 1041-1050.
40. Papandreou I, Powell A, Lim AL, and Denko N (2005). Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 569, 87-100.
41. Koch CJ, Kruuv J, and Frey HE (1973). The effect of hypoxia on the generation time of mammalian cells. Radiat Res 53, 43-52.
42. Thomlinson RH (1982). Measurement and management of carcinoma of the breast. Clin Radiol 33, 481-493.
43. Evan GI and Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
44. Moon EJ, Brizel DM, Chi JT, and Dewhirst MW (2007). The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 9, 1237-1294.
45. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, and Karttunen TJ (1998). Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am] Pathol 153, 279-285.
46. Hoskin PJ, Sibtain A, Daley FM, and Wilson GD (2003). GLUTl and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89, 1290-1297.
47. Hoogsteen IJ, Marres HA, Wijffels KI, Rijken PF, Peters JP, van den Hoogen FJ, Oosterwijk E, van der Kogel AJ, and Kaanders JH (2005). Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11, 97-106.
48. Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM, and Overgaard J (1996). The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35, 701-708.
49. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, and Raleigh JA (1998). Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71, 270-277.
50. Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, and Varia MA (1997). Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37, 897-905.
51. Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen FJ, Marres HA, de Wilde PC, Raleigh JA, and van der Kogel AJ (2000). Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 83, 674-683.
52. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, and Van Meir EG (2004). Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64, 920-927.
53. Kal HB (1973). Proliferation behaviour of P and Q cells in a rat rhabdomyosarcoma after irradiation as determined by DNA measurements. Eur J Cancer 9, 753-756.
54. Koch CJ, Kruuv J, Frey HE, and Snyder RA (1973). Plateau phase in growth induced by extreme hypoxia. Int J Radiat Biol 23, 67-74.